|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/20 Nymox Pharmaceutical Corp 20-F 12/31/19 107:5.1M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual Report by a Foreign Non-Canadian Issuer HTML 722K
4: EX-13.A Annual or Quarterly Report to Security Holders HTML 25K
5: EX-13.B Annual or Quarterly Report to Security Holders HTML 25K
2: EX-12.A Statement re: Computation of Ratios HTML 30K
3: EX-12.B Statement re: Computation of Ratios HTML 30K
59: R1 Document and Entity Information HTML 54K
92: R2 Consolidated Statements of Comprehensive Income HTML 78K
82: R3 Consolidated Statements of Financial Position HTML 87K
22: R4 Consolidated Statements of Financial Position HTML 28K
(Parenthetical)
58: R5 Consolidated Statements of Cash Flow HTML 93K
91: R6 Consolidated Statements of Changes in Equity HTML 73K
81: R7 Business Activities and Basis of Presentation HTML 37K
21: R8 Going Concern Considerations HTML 30K
60: R9 Significant Estimates HTML 28K
97: R10 Significant Accounting Policies HTML 76K
62: R11 New Accounting Standards and Interpretations HTML 30K
27: R12 Property and Equipment HTML 89K
39: R13 Intangible Assets HTML 29K
96: R14 Accounts Payable and Accrued Liabilities HTML 38K
61: R15 Convertible Notes HTML 40K
26: R16 Operating Leases and Commitments HTML 42K
38: R17 Share Capital HTML 41K
95: R18 Stock Options HTML 51K
63: R19 Share Based Compensation HTML 37K
19: R20 Warrants HTML 59K
57: R21 Income Taxes HTML 60K
94: R22 Earnings Per Share HTML 35K
84: R23 Financial Instruments Fair Value Disclosures HTML 29K
18: R24 Finance Income and Finance Costs HTML 52K
56: R25 Segment Disclosures HTML 43K
93: R26 Concentrations HTML 32K
83: R27 Related Party Transactions HTML 39K
20: R28 Research and Development Expenses HTML 40K
55: R29 Personnel Expenses HTML 37K
35: R30 Capital Disclosures and Financial Risk HTML 29K
24: R31 Foreign Exchange Risk HTML 28K
64: R32 Credit Risk HTML 30K
98: R33 Interest Rate Risk HTML 27K
36: R34 Liquidity Risk HTML 33K
25: R35 Subsequent Events HTML 28K
65: R36 Significant Accounting Policies (Policies) HTML 127K
99: R37 Significant Accounting Policies (Tables) HTML 29K
37: R38 Property and Equipment (Tables) HTML 88K
23: R39 Accounts Payable and Accrued Liabilities (Tables) HTML 37K
51: R40 Convertible Notes (Tables) HTML 35K
16: R41 Commitments and Contingencies (Tables) HTML 38K
75: R42 Share Capital (Tables) HTML 36K
85: R43 Stock Options (Tables) HTML 55K
52: R44 Share Based Compensation (Tables) HTML 34K
17: R45 Warrants (Tables) HTML 55K
76: R46 Income Taxes (Tables) HTML 65K
86: R47 Earnings Per Share (Tables) HTML 33K
53: R48 Finance Income and Finance Costs (Tables) HTML 51K
15: R49 Segment Disclosures (Tables) HTML 42K
33: R50 Concentrations (Tables) HTML 31K
47: R51 Related Party Transactions (Tables) HTML 35K
101: R52 Research and Development Expenses (Tables) HTML 39K
68: R53 Personnel Expenses (Tables) HTML 36K
32: R54 Liquidity risk (Tables) HTML 31K
46: R55 Significant Accounting Policies (Details) HTML 33K
100: R56 Significant Accounting Policies (Details HTML 28K
Narrative)
67: R57 New Accounting Standards and Interpretations HTML 35K
(Details Narrative)
34: R58 Property and Equipment (Details) HTML 60K
45: R59 Property and Equipment (Details Narrative) HTML 28K
90: R60 Intangible Assets (Details Narrative) HTML 38K
79: R61 Accounts Payable and Accrued Liabilities (Details) HTML 34K
14: R62 Convertible Notes (Details) HTML 32K
50: R63 Convertible Notes (Details Narrative) HTML 40K
88: R64 Operating Leases and Commitments (Details) HTML 31K
77: R65 Operating Leases and Commitments (Details 1) HTML 34K
12: R66 Operating Leases and Commitments (Details HTML 40K
Narrative)
48: R67 Share Capital (Details) HTML 30K
87: R68 Share Capital (Details Narrative) HTML 40K
80: R69 Stock Options (Details) HTML 52K
71: R70 Stock Options (Details 1) HTML 43K
102: R71 Stock Options (Details Narrative) HTML 30K
41: R72 Share Based Compensation (Details) HTML 34K
28: R73 Share Based Compensation (Details Narrative) HTML 38K
74: R74 Warrants (Details) HTML 48K
105: R75 Warrants (Details Narrative) HTML 36K
44: R76 Income Taxes (Details) HTML 43K
31: R77 Income Taxes (Details 1) HTML 33K
69: R78 Income Taxes (Details 2) HTML 84K
106: R79 Income Taxes (Details Narrative) HTML 28K
72: R80 Earnings Per Share (Details) HTML 31K
103: R81 Financial Instruments Fair Value Disclosures HTML 34K
(Details Narrative)
42: R82 Finance Income and Finance Costs (Details) HTML 47K
29: R83 Segment Disclosures (Details) HTML 43K
73: R84 Concentrations (Details) HTML 32K
104: R85 Related Party Transactions (Details) HTML 36K
43: R86 Related Party Transactions (Details Narrative) HTML 36K
30: R87 Research and Development Expenses (Details) HTML 41K
70: R88 Personnel Expenses (Details) HTML 35K
107: R89 Capital Disclosures and Financial Risk (Details HTML 39K
Narrative)
89: R90 Foreign Exchange risk (Details Narrative) HTML 28K
78: R91 Credit risk (Details Narrative) HTML 34K
13: R92 Interest rate risk (Details Narrative) HTML 27K
49: R93 Liquidity risk (Details) HTML 35K
66: XML IDEA XML File -- Filing Summary XML 195K
40: EXCEL IDEA Workbook of Financial Reports XLSX 101K
6: EX-101.INS XBRL Instance -- nymx-20191231 XML 1.64M
8: EX-101.CAL XBRL Calculations -- nymx-20191231_cal XML 146K
9: EX-101.DEF XBRL Definitions -- nymx-20191231_def XML 448K
10: EX-101.LAB XBRL Labels -- nymx-20191231_lab XML 907K
11: EX-101.PRE XBRL Presentations -- nymx-20191231_pre XML 735K
7: EX-101.SCH XBRL Schema -- nymx-20191231 XSD 307K
54: ZIP XBRL Zipped Folder -- 0001640334-20-000668-xbrl Zip 133K
EXHIBIT 12 (b)
CERTIFICATION
I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that:
| 1. | I have reviewed this annual report for the period ended December 31, 2019 of Nymox Pharmaceutical Corporation; |
|
| |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
| |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
|
| |
| 4. | The company s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a 15(e) and 15d 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a 15(f) and 15d 15(f)) for the company based on the COSO 1992 framework and we have: |
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
|
| ||
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with international financial reporting standards; | |
|
| ||
| c) | evaluated the effectiveness of the company s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
|
| ||
| d) | disclosed in this report any change in the company s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company s internal control over financial reporting; and |
| 5. | The company s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company s auditors and the audit committee of the company s board of directors (or persons performing the equivalent function): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company s ability to record, process, summarize and report financial information; and | |
|
| ||
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company s internal control over financial reporting. |
| Date: March 30, 2020 |
||
|
| ||
| By: | /s/ Erik Danielsen | |
| Chief Financial Officer Nymox Pharmaceutical Corporation | ||
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/20 | None on these Dates | ||
| For Period end: | 12/31/19 | |||
| List all Filings | ||||